Elekta (EKTA) Strategy update summary

Strategic transformation and direction

• Four must-win battles identified: simplify/empower/speed, focused innovation, win in the US, and expand in China, with ongoing COGS reduction.

• New operating model aims for over SEK 500 million in annual savings, with restructuring costs of SEK 450–500 million and a workforce reduction of 450 employees.

• Decentralization to regions and business lines, and recruitment of new leadership including CFO, COO, and Head of HR, to increase accountability and speed.

• Execution of transformation is on track, with full effect expected by Q4 or Q1 of fiscal 2026/27.

• Detailed financial plans and targets to be presented at a Capital Markets Day in June 2026 in Stockholm.

Innovation and product portfolio

• Shift from long, engineering-driven innovation cycles to faster, customer-driven cycles for higher ROI.

• Continued R&D investment above MedTech industry average, with 11–14% of sales allocated over five years.

• Focus on integrating devices and software for workflow-driven solutions, especially Elekta ONE.

• Product and Technology Office created, reporting directly to CEO, to streamline decision-making.

• Emphasis on software-enabled treatments and life cycle management for long-term customer partnerships.

Regional strategies: China and US

• China: Maintains 40–45% linac market share, focusing on localization, innovation partnerships, and expansion into underserved segments.

• US: Recent FDA clearance for EVO platform expected to drive market share gains and revenue, targeting both replacement and upgrade opportunities.

• US strategy leverages adaptive therapy and integrated software to address evolving clinical and financial needs.

• Both regions emphasize training, education, and tailored solutions to sustain growth.